Biological E gets DGCA nod to begin the next phase of trials for its COVID-19 vaccine

This vaccine candidate includes an antigen that was in-licensed from BCM Ventures, which is an integrated commercialisation team of Baylor College of Medicine in Houston, and an advanced adjuvant from the US-based vaccine focused pharmaceutical firm Dynavax Technologies Corporation.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news